
The Metabolic Link Targeting Cancer Metabolism: The Future of Oncology | Dr. Tomás Duraj | The Metabolic Link Ep. 61
10 snips
Feb 11, 2025 Dr. Tomás Duraj, a physician-scientist specializing in cancer metabolism, discusses revolutionary insights on targeting cancer through its metabolism. He explains how mitochondrial dysfunction underpins cancer development and explores the Warburg effect, emphasizing the need to target both glucose and glutamine metabolism. Duraj advocates for ketogenic therapy combined with standard treatments to create a hostile environment for tumors. He also highlights innovative imaging techniques and the potential for broader applications of metabolic strategies across various cancer types.
AI Snips
Chapters
Transcript
Episode notes
Path From MD To Metabolic Oncology
- Dr. Tomás Duraj trained as a medical doctor in Madrid and then pivoted to a PhD in cancer metabolism.
- He joined Dr. Thomas Seyfried's lab to bridge bench research and translational clinical strategies.
Compare Tumors To Matched Normal Cells
- Comparing tumor cells with matched normal cells reveals metabolic flexibilities and essential fuel dependencies.
- Such comparisons clarify whether ketones, fatty acids, or lactate can truly substitute for glucose/glutamine.
Mitochondria As A Primary Driver
- Mitochondrial dysfunction can be a primary driver of malignant transformation rather than just downstream of mutations.
- Restoring efficient oxidative phosphorylation could reverse cancer phenotype despite existing mutations.
